SUGARDOWN is Boston Therapeutics’ currently marketed dietary supplement that is intended to support healthy blood sugar. In addition, clinical studies indicate that SUGARDOWN can maintain healthy glucose levels even after-meals when sugar tends to spike.
Boston Therapeutics CEO David Platt the combination of its commitment to complex carbohydrate drug chemistry and Benchworks’ marketing expertise should be a key element of its future growth, and specifically in growing sales and broadening awareness of the potential benefits of SUGARDOWN.
Benchworks will take a three-pronged approach to position SUGARDOWN as an adjunct to diet and exercise beyond the current intended use as a dietary supplement by individuals who want to more effectively manage their health with a focus on proper glucose metabolism and blood sugar levels.
The expanded three-pronged approach will include: (1) increasing awareness among people who may be at risk of developing diabetes, and their care givers; (2) creating a bond with healthcare educators and nutritionists who would recommend SUGARDOWN for their patients, and (3) strengthening SUGARDOWN’s medical profile by continuing to build on new data from additional clinical trial results and new scientific findings.
In 2012, Boston Therapeutics announced the results of a clinical study conducted at the University of Sydney in Australia that showed the post-meal incremental area under the curve (iAUC) for glucose and insulin were lower following consumption of SUGARDOWN prior to a high carbohydrate meal of rice in a dose-dependent manner.
This resulted in a reduction in post-meal elevation of blood glucose compared with the rice consumed alone. On average, there was a 32 percent reduction in the post-meal iAUC for glucose and a 24 percent reduction in post-meal insulin response for the volunteers in the study. SUGARDOWN was tested in healthy, but overweight adults with a mean body mass index (BMI) value of 27.3kg/m2.